From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
Parameter
HR for Covariate
Placebo Titration
Axitinib Titration
Metastatic site (≥3 vs. ≤2)
2.191
4.438
Time from histopathological diagnosis to treatment (< 1 vs. ≥1 year)
1.437
3.569
Baseline Hb < LLN (yes vs. no)
0.940
3.378